Category: by country

Journal retracts nine papers in one day by author under investigation at the Weizmann Institute

On April 27, the Journal of Biological Chemistry (JBC) retracted nine papers by a researcher based in Israel, including some dating back to 2000.

The reason: Image manipulation.

Michal Neeman, vice president of The Weizmann Institute of Science, told us that the researcher, Rony Seger, is under investigation following an allegation of misconduct affecting papers in multiple journals.

So far, we’ve found 11 retractions for papers by Seger, a molecular biologist. In the notices, the authors state they have “full confidence” in the findings, and in many instances have replicated the work.

According to Neeman:

Continue reading Journal retracts nine papers in one day by author under investigation at the Weizmann Institute

Publisher blames bad choice of reviewer for publication of hoax paper on penis as “social construct” 

Less than a week after publishing a much-discussed hoax paper, a scholarly publisher has acknowledged that it had chosen reviewers for the paper whose “expertise did not fully align with this subject matter.”

The subject matter: that the penis should not be considered an anatomical organ, but more as a concept – “a gender-performative, highly fluid social construct.” Upon publication, the authors immediately admitted the paper was a prank, arguing that its publication illustrates a lack of intellectual and scientific rigor in some social sciences, especially gender studies. But others have questioned whether it really demonstrates that at all.

In response to the revelation of the hoax, Taylor & Francis associate editorial director Emma Greenword published a statement about the process that led to this entanglement: Continue reading Publisher blames bad choice of reviewer for publication of hoax paper on penis as “social construct” 

Authors retract much-debated blockchain paper from F1000

The authors of a popular — and heavily debated — F1000Research paper proposing a method to prevent scientific misconduct have decided to retract it.

The paper was initially criticized for allegedly plagiarizing from a graduate student’s blog — and revised to try to “rectify the overlap.” But according to F1000, it is now being retracted after an additional expert identified problems with the methodology.

Today, F1000 added this editorial note to the paper:

Continue reading Authors retract much-debated blockchain paper from F1000

Author retracts nanotechnology paper over doubts about key results

The corresponding author of a 2015 nanotechnology paper has penned a lengthy — and revealing — retraction notice, explaining why he is not certain about the findings.

In the notice, Chang Ming Li from the Institute for Clean Energy & Advanced Materials (ICEAM) at Southwest University in China, states that there is “insufficient evidence to conclusively” identify the composition of the nanowire array described in the article, which “severely undermines the validity of the reported conclusions.”

The 2015 paper has been considered “highly cited” by Clarivate Analytics’ Web of Science, formerly part of Thomson Reuters, meaning it has received a disproportionate amount of cites given its field and publication year.

Li also said that the paper — which appeared in Physical Chemistry, Chemical Physics — was “submitted and published without my knowledge or permission.” He has not responded to our request to explain how that could have happened, given that he was the corresponding author. Continue reading Author retracts nanotechnology paper over doubts about key results

Reuters removes story on gender confirmation surgery because firm mistakenly released data

Reuters has removed a story about gender confirmation surgery, saying it included problematic data.

The public relations firm representing the American Society of Plastic Surgeons (ASPS) — which generated the data in the report  — took responsibility, saying it supplied Reuters with data the ASPS did not want released.

Yesterday, Reuters pulled its version of a widely-reported story about an increase in such surgeries in the U.S. (Later, it pulled the withdrawal notice as well, only to make it reappear at a different URL.)

The story, originally posted just after midnight yesterday, reported a 19 percent increase in those procedures from 2015 to 2016, based on data provided the American Society of Plastic Surgeons (ASPS). Around 1 pm US Eastern time that day, Reuters put up a withdrawal notice in place of the original story:

Continue reading Reuters removes story on gender confirmation surgery because firm mistakenly released data

Researchers mistakenly administer three-fold higher dose of anesthesia

Researchers have retracted a 2016 paper after discovering that they accidentally administered three times the reported dose of anesthesia to rats.

In the Experimental Physiology paper, the authors set out to mathematically map how rats’ blood pressure changes under different conditions, which required the rats to be anesthetized. But their findings were called into question when they found the rats had received a much higher concentration of anesthesia than intended. According to the notice, this higher dose compromised the “objectives of the experiment.”

The corresponding author Karol Ondrias, from the Institute of Molecular Physiology and Genetics at the Slovak Academy of Sciences in Bratislava, told us how the dosing error occurred: Continue reading Researchers mistakenly administer three-fold higher dose of anesthesia

Ex-PhD candidate sues advisor, school: Colorado prof “poisoned the well” after research dispute

A former University of Colorado Boulder graduate student is suing his ex-advisor for defamation after being shooed out midway through his doctoral program.

Robert Roscow says he had to leave CU Boulder’s department of Ecology and Evolutionary Biology (EBIO) in the fall of 2016 with only a master’s degree after fish evolution researcher David Stock dropped him as a student. Their relationship deteriorated following a dispute about whether another student should perform experiments Roscow considered to be essential to his dissertation.

Once dropped, Roscow was offered the chance to find another advisor, but never did. In his complaint, filed April 25 in Boulder County District Court, Roscow claims he has evidence that Stock “poisoned the well” by badmouthing him in email and in person to other professors, ultimately preventing Roscow from completing his degree.

As first reported by BusinessDen, Roscow is also suing CU Boulder for a breach of contract and for failing to “provide [him] with the reasonable opportunity to pursue his PhD,” among other allegations. 

CU Boulder declined to elaborate on the case. Chief Spokesperson Ryan Huff told us:

Continue reading Ex-PhD candidate sues advisor, school: Colorado prof “poisoned the well” after research dispute

Denmark to institute sweeping changes in handling misconduct

In six weeks, new policies for handling misconduct in Denmark will go into effect, which alter the definition of misconduct and establish clear policies for who handles such allegations.

Starting July 1, research misconduct will be limited to how it’s typically defined elsewhere — fabrication, falsification, and plagiarism (the previous definition included serious breaches of good scientific practices). All such allegations will be investigated by a central body, The Board for the Prevention of Scientific Misconduct — not at the institutions where the allegations are focused, as it has been in the past. Institutions, however, will remain responsible for investigating allegations of so-called Questionable Research Practices (QRPs) — such as only reporting data that support your hypothesis — and must publicize their policies for handling (QRPs).

The Board for the Prevention of Scientific Misconduct will replace the Danish Committees on Scientific Dishonesty (DCSD).

You can read the press release from the Ministry of Higher Education and Science here. We translated it into English, here.

Continue reading Denmark to institute sweeping changes in handling misconduct

Four in 10 biomedical papers out of China are tainted by misconduct, says new survey

Chinese biomedical researchers estimate that 40% of research in their country has been affected in some way by misconduct, according to a new survey.

The authors are quick to caution against putting too much stock in this figure due to the subjective nature of the survey, published in Science and Engineering Ethics. The estimates also spanned a wide range, with a standard deviation of ±24%. But they say that the responses to this question and others on the survey suggest that scientists in the region feel academic misconduct remains a major problem that authorities have failed to adequately address. (Indeed, a recent analysis from Quartz using Retraction Watch data showed that researchers based in China publish more papers retracted for fake peer reviews than all other countries put together.)

The survey was designed by employees at Medjaden, a Hong Kong-based editing company that assists mainland Chinese biomedical researchers publishing in English-language journals. They invited all of their registered users by email to complete two surveys—roughly 10,000 users in 2010 and 15,000 in 2015. Like most online surveys, this one had a low response rate—around 5%, so caveats about sampling bias apply.

Study co-author Hua He, who is also Medjaden’s CEO, said:

Continue reading Four in 10 biomedical papers out of China are tainted by misconduct, says new survey

Could bogus scientific results be considered false advertising?

Could a scientific paper ever be considered an advertisement?

That was the question posed to a Tokyo court, in a criminal case where prosecutors argued — at the behest of Japan’s ministry of health — that a peer-reviewed paper containing faked data should be considered “fraudulent or exaggerated advertising” under that country’s laws.

In that case, however, the argument didn’t work. In March, the court decided that a fraudulent paper was not false advertising, allowing a pharmaceutical researcher at a Novartis subsidiary to escape jail time. The decision also cleared Novartis of charges and helped the company avoid a ¥4 million ($35,373 USD) fine.

According to an article in The Japan Times, the presiding judge Yasuo Tsujikawa said:

Continue reading Could bogus scientific results be considered false advertising?